RNAimmune

RNAimmune

The company's focus is on developing treatments and cures for complex diseases using mrna technology.

HQ location
Gaithersburg, United States
Launch date
Employees
Enterprise value
$108—162m
  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor

€0.0

round
investor investor investor investor investor investor

€0.0

round
*

$27.0m

Series A
Total Funding000k
More about RNAimmune
Made with AI
Edit

RNAimmune is a biotechnology startup specializing in messenger RNA (mRNA) technology. The company focuses on developing treatments for cancer, antibody therapies, rare diseases, and prophylactic vaccines. RNAimmune's proprietary technology uses mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company operates in the biotechnology and pharmaceutical markets, serving clients in the healthcare sector, including hospitals, research institutions, and pharmaceutical companies. RNAimmune generates revenue through the development and licensing of its mRNA-based therapies and vaccines. The company's leadership team includes industry veterans with extensive experience in drug development and pharmaceutical research, ensuring a strong foundation for innovation and growth.

Keywords: mRNA technology, cancer therapies, antibody treatments, rare diseases, vaccines, biotechnology, pharmaceutical, healthcare, drug development, innovation.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo